Moleculin Biotech (MBRX) Projected to Post Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) is expected to be releasing its earnings data before the market opens on Friday, March 21st. Analysts expect Moleculin Biotech to post earnings of ($1.25) per share for the quarter.

Moleculin Biotech Stock Performance

MBRX stock traded up $0.05 during trading on Thursday, hitting $1.09. The company had a trading volume of 451,309 shares, compared to its average volume of 1,396,513. The firm has a 50-day moving average price of $1.38 and a 200-day moving average price of $2.04. Moleculin Biotech has a 12 month low of $0.40 and a 12 month high of $7.80.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on MBRX. Maxim Group cut shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. StockNews.com started coverage on shares of Moleculin Biotech in a research report on Thursday, March 13th. They set a “sell” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Moleculin Biotech in a research report on Monday, March 3rd.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.